BS EN 13707:2013
Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies
PDF) Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. - Abstract - Europe PMC
Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of
Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection | PLOS Computational Biology
BS EN 13707:2013
Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection | PLOS Computational Biology
BS EN 13707:2013
PDF) Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies | PLOS Pathogens
Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV- 1
Functional development of a V3/glycan- specific broadly neutralizing antibody isolated from a case of HIV superinfection
Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques | PLOS Pathogens
Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies
Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques | PLOS Pathogens
Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection | PLOS Computational Biology
Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies | PLOS Pathogens
Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of
Role of cytokine agonists and immune checkpoint inhibitors toward HIV remission
